Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)
针对不可切除的肝细胞癌患者，采用度伐利尤单抗、曲美利木单抗和贝伐珠单抗进行序贯或直接三联治疗：MONTBLANC 试验方案 (AIO-HEP-0325/ass)
期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359261417640
Ben Khaled, Najib; Ehmer, Ursula; Kubisch, Ilja; Gonzalez-Carmona, Maria A; Philipp, Alexander; Seidensticker, Max; Altenhofer, Julia; Basch, Marion; Hüwer, Tim; Oehrle, Bettina; Geier, Andreas; Soldà, Caterina; Auriemma, Alessandra; Bauer, Ulrike; Zhou, Taotao; Perkhofer, Lukas; Chater, Jack; Weinmann, Arndt; von Felden, Johann; De Rosa, Antonio; Vivaldi, Caterina; Piseddu, Ignazio; Schwald, Isabel; Enssle, Stefan; Karin, Monika; Schneider, Julia S; Gröper, Moritz N; Ondrejkova, Katarina; Weiss, Lena; Beyer, Georg; Schulze, Kornelius; Antonuzzo, Lorenzo; Masi, Gianluca; Daniele, Bruno; Ricke, Jens; Mayerle, Julia; Foerster, Friedrich; Reiter, Florian P; Ettrich, Thomas J; De Toni, Enrico N
